Header

UZH-Logo

Maintenance Infos

Molecular targets for therapy in systemic sclerosis


Iwamoto, Naoki; Distler, Oliver (2012). Molecular targets for therapy in systemic sclerosis. Fibrogenesis & Tissue Repair, 5(Suppl 1):S19.

Abstract

Despite significant advances have been made in the recent years regarding organ-specific therapies, there is no approved 'disease-modifying' antifibrotic drug for systemic sclerosis (SSc) available to date. Although non-selective immunosuppressive agents are routinely used to treat patients with SSc, large well-controlled studies are lacking for almost all immunosuppressive agents and further evidence is required for long-term beneficial effects of these drugs. Considering these facts about immunosuppressive agents in SSc and also considering the high mortality of SSc, other therapeutic strategies are urgently needed. Recently an important role of the 5-hydroxytryptamine (5-HT: serotonin) pathway in fibrosis was reported. In this review, we discuss the role of 5-HT in fibrosis and therapeutic potential of this molecule. Besides 5-HT, there are a number of promising targets that have been extensively characterized in recent years. For many of these molecular targets, modifiers are readily available for clinical studies, and often these modifiers are used already in clinical use for other diseases. Results from these studies will show, in how far the promising preclinical results for novel antifibrotic strategies can be translated to clinical practice.

Abstract

Despite significant advances have been made in the recent years regarding organ-specific therapies, there is no approved 'disease-modifying' antifibrotic drug for systemic sclerosis (SSc) available to date. Although non-selective immunosuppressive agents are routinely used to treat patients with SSc, large well-controlled studies are lacking for almost all immunosuppressive agents and further evidence is required for long-term beneficial effects of these drugs. Considering these facts about immunosuppressive agents in SSc and also considering the high mortality of SSc, other therapeutic strategies are urgently needed. Recently an important role of the 5-hydroxytryptamine (5-HT: serotonin) pathway in fibrosis was reported. In this review, we discuss the role of 5-HT in fibrosis and therapeutic potential of this molecule. Besides 5-HT, there are a number of promising targets that have been extensively characterized in recent years. For many of these molecular targets, modifiers are readily available for clinical studies, and often these modifiers are used already in clinical use for other diseases. Results from these studies will show, in how far the promising preclinical results for novel antifibrotic strategies can be translated to clinical practice.

Statistics

Citations

Altmetrics

Downloads

42 downloads since deposited on 15 Feb 2013
8 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2012
Deposited On:15 Feb 2013 07:42
Last Modified:07 Dec 2017 19:13
Publisher:BioMed Central
ISSN:1755-1536
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1186/1755-1536-5-S1-S19
PubMed ID:23259845

Download

Download PDF  'Molecular targets for therapy in systemic sclerosis'.
Preview
Content: Published Version
Filetype: PDF
Size: 224kB
View at publisher
Licence: Creative Commons: Attribution 2.0 Generic (CC BY 2.0)
Filetype: Other (Coversheet Pages conversion from application/pdf to application/pdf)